^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

PD-L1 amplification

i
Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Entrez ID:
Related biomarkers:
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
12/06/2022
Initiation :
01/13/2017
Primary completion :
10/31/2023
Completion :
10/31/2023
CD4
|
PD-L1 overexpression • PD-L1 amplification
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • MK-1088
Phase 2
German Cancer Research Center
Not yet recruiting
Last update posted :
09/14/2022
Initiation :
12/01/2022
Primary completion :
04/01/2029
Completion :
12/01/2029
HER-2 • PD-L1 • PIK3CA • TMB • BRCA1 • BRCA2 • TROP2 • PARP1
|
HER-2 positive • BRCA2 mutation • BRCA1 mutation • TMB-H • MSI-H/dMMR • HR positive • PIK3CA mutation • HER-2 negative • HER-2 exon 20 insertion • PD-L1 amplification • HER-2 exon 20 mutation • HR positive + HER-2 negative • UGT1A1*28 • UGT1A1*1*1 • HER-2 exon 23 mutation
|
Herceptin (trastuzumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Perjeta (pertuzumab) • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • inavolisib (GDC-0077) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1/2
Asan Medical Center
Unknown status
Last update posted :
12/03/2019
Initiation :
06/11/2018
Primary completion :
06/30/2021
Completion :
06/30/2021
PD-L1 • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3 • PMS1 • POLD2
|
MSI-H/dMMR • PD-L1 amplification • POLD1 mutation • MSH2 mutation • MLH1 mutation • MSH3 mutation • PMS2 mutation • MLH3 mutation • PMS1 mutation • POLD2 mutation
|
Imfinzi (durvalumab) • paclitaxel • Imjudo (tremelimumab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)